GDRX vs IART
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GDRX exhibits a fragile financial profile with a Piotroski F-Score of 4/9, indicating only marginal stability. The stock is currently trading at $2.16, which is a premium to its Graham Number ($1.91) and significantly above its growth-based intrinsic value ($0.63). Fundamental decay is evident through negative YoY revenue (-1.90%) and earnings growth (-9.70%), compounded by a streak of four consecutive earnings misses. With a 5-year price collapse of 94.7% and bearish insider sentiment, the data suggests a company in a structural decline.
IART presents as a classic deep-value turnaround candidate with a stable Piotroski F-Score of 6/9, indicating reasonable operational health despite severe price depreciation. The company is trading at a significant discount to book value (P/B 0.74) and possesses a very low forward P/E of 3.86, suggesting the market has over-priced the risk. However, negative net profit margins (-31.58%) and stagnant revenue growth (-1.70%) offset the valuation appeal. The stark contrast between the current price ($9.90) and the analyst target ($15.57) indicates potential upside, but the bearish technical trend remains a primary headwind.
Compare Another Pair
Related Comparisons
GDRX vs IART: Head-to-Head Comparison
This page compares GoodRx Holdings, Inc. (GDRX) and Integra LifeSciences Holdings Corporation (IART) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.